The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ravi Agrawal, Trustee Ravi Agrawal Trust
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Ravi Agrawal, Trustee of Ravi Agrawal Trust (a promoter of Ajanta Pharma), sold 34,50,000 equity shares (2.76% of paid-up capital) in the open market on June 9, 2026. Before the sale, the Trust held 1,62,42,904 shares (13.00%); after the sale, its holding stands at 1,27,92,904 shares (10.24%). The total equity capital of the company remains unchanged at 12,49,35,624 shares of ₹2 each. Encumbered shares held by the Trust stood at 57,56,777 (4.61%), unchanged by this transaction. The sale was disclosed under SEBI SAST Regulations, 2011.
A promoter trimming a meaningful 2.76% stake in the open market in a single day can be perceived negatively by retail investors and may exert short-term pressure on the stock price. However, the Trust still retains a significant 10.24% holding, and no change in encumbered shares suggests this is a portfolio rebalancing rather than a distress-driven exit.